AB0166 MORTALITY AND COMORBIDITIES IN A COHORT OF PACIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS
Authors: J. Calvo Gutierrez, B. Rodríguez Jiménez, M. L. Ladehesa Pineda, M. Rojas-Giménez, R. Ortega Castro, A. Escudero Contreras
Journal: Annals of the Rheumatic Diseases (2021)

Background: Patients diagnosed with Rheumatoid Arthritis (RA) have an increased risk of comorbidities and secondary mortality, in a large extent due to cardiovascular events. Objectives: To identify the frequency of comorbidity, mortality and variables related to its increase in a cohort of patients with rheumatoid arthritis established (RAE). Methods: Controlled cross-sectional observational study of a cohort of 188 patients with RAE a 10 year follow-up (5 years if not complete this period). Results: 62.8% were women, mean age of patients at the time of inclusion was high 73.3 (+/-13.8) years and mean duration of disease was 12,8 (+/-6,99) years. Regarding CV risk factors, 26.6% smoked, 60.6% hypertension and 52.1 % diabetic. Regarding comorbidities, the most frequent were serious infections (45.2%), CVD (35.1%), Osteoporosis (31.9%), Depression (31.9%) and Kidney disease (26.6%). During follow-up, an improvement was observed inflammatory parameters and activity levels (p &lt;0.001) Table 1. Mortality was associated to CVD and severe infection, and depression to lower mortality (p 0.05). Overall mortality was 32.4%. A logistic regression was performed in the group of patients with time greater evolution 10 years of our cohort, to be able to better represent the influence of disease carrying with her for longer, whose results are shown in Table 2. Analysand survival, men, CVD, severe infections, and Positive Rheumatoid Factor were associated with higher mortality, while treatment with Methotrexate was associated with increased survival. Among the causes of death, the most frequent were infections, CVD and solid cancer. Conclusion: -The incidence of comorbidities in our cohort is similar to that described in the literature. -Relationship between mortality and CVD and severe infection is demonstrated. -The mortality rate observed is higher than that described in the literature, which be influenced by the advanced age of the patients in the cohort and high time evolution of RA. References: [1]Lee YK, Ahn GY, Lee J, Shin JM, Lee TH, Park DJ, Song YJ, Kim MK, Bae SC. Excess mortality persists in patients with rheumatoid arthritis. Int J Rheum Dis. 2021 Jan 19. doi: 10.1111/1756-185X.14058. Epub ahead of print. PMID: 33463890. [2]Mikuls, T. R. (2003). Co-morbidity in rheumatoid arthritis. Best Practice &amp; Research Clinical Rheumatology, 17(5), 729-752. [3]Naz, S. M., &amp; Symmons, D. P. M. (2007). Mortality in established rheumatoid arthritis. Best Practice &amp; Research Clinical Rheumatology, 21(5), 871-883. Table 1. Student’s t test for paired data. Variables Basal 10 year P DAS28 5,25 (15,08) 2,89 (1,06) 0,036 VAS 38,61 (36,45) 26,93 (24,97) &lt;0,001 HAQ 1,04 (0,79) 0,88 (0,87) NS TJC 4,96 (5,38) 1,40 (2,57) &lt;0,001 SJC 3,55 (3,69) 0,72 (2,11) &lt;0,001 ESR (mm/h ) 31,47 (21,19) 25,86 (18,47) &lt;0,001 CRP (mg/L ) 15,24 (16,13) 9,41 (21,02) 0,001 Hemoglobin (mg/dL ) 13,44 (7,92) 13,52 (7,64) NS Glucose (mg/dL ) 102,26(35,97) 103,83 (37, 98) NS Cholesterol (mg/dL ) 203,56 (46,11) 195,65 (38,12) 0,042 LDL (mg/dL ) 123,91 (40,69) 119,58 (33,89) NS HDL (mg/dL ) 56,73 (19,07) 54,84 (20,38) NS Triglycerides (mg/dL ) 110,85 (60,77) 113,44 (55,61) NS Table 2. Logistic regression model. Hosmer-Lemeshow Chi square 9.035 Gl 7 p 0.25. Likelihood ratio test Chi square 64.658 Gl 5 p &lt;0.001. NS, Not significant. Variable Univariate analysis OR (IC 95% ) p Multiivariate analysis FINAL MODELO OR (IC 95% ) P Dyslipidemia 1,02 (0,47-2,23) 0,965 HT 4,73 (1,79-12,48) 0,002 DM 1,42 (0,59-3,44) 0,438 CV disease 11,25 (4,45-28,44) &lt; 0,001 12,33 (3.89-39,04) &lt; 0,001 Hyperuricemia 3,27 (1,39-7,65) 0,006 Thyroid disease 0,56 (0,15-2,11) 0,393 Interstitial lung disease 2,48 (0,77-7,99) 0,127 7,37 (1,48-36,84) 0,015 Osteoporosis 2,38 (1,07-5,29) 0,033 Renal disease 8,25 (3,41-19,97) &lt; 0,001 4,14 (1,34-12,80) 0,014 Depressión 0,32 (0,12-0,84) 0,021 0,20 (0,06-0,74) 0,015 Solyd CA 1,12 (0,44-2,87) 0,809 Hematologic CA &lt;0,001 (NS) 0,999 Amyloidosis 2,65 (0,16-43,52) 0,496 Severe infecction 6,22 (2,53-15,29) &lt; 0,001 5,59 (1,66-18,79) 0,005 COVID-19 infection 1,31 (0,12-14,91) 0,828 Disclosure of Interests: None declared